EurekaMag
+ Translate
+ Most Popular
Spermatogenic and steroidogenic impairment after chromium treatment in rats
Prediction of enthalpy of formation based on refined crystal structures of multisite compounds; Part 1, Theories and examples
Intrastromal photorefractive keratectomy for myopia by Nd:YLF picosecond laser
Teachers' beliefs about the role of prior language knowledge in learning and how these influence teaching practices
Classification and genesis of submarine iron-manganese deposits
Insecta a Cl. G. N. Potanin in China et in Mongolia novissime lecta. XVII. Hemiptera-Heteroptera
On the occurrence of the splendid genus Machaerothrix Haupt in Tsushima, with some remarks on the genus (Hymenoptera, Pompilidae)
Enamel craze lines
Gynecologic examination of the child and the adolescent
Periosteal osteoclasts, skeletal development and ageing
Fibrodysplasia ossificans progressiva in a Nigerian: a case report
The chronically ill patient with anorexia nervosa development, phenomenology, and therapeutic considerations
Kummelonautilus taiwanum sp. nov. (Nautilida) from the early Miocene Shihmen Formation, Chungliao, Nantou, west-central Taiwan
Efficacy of Droncit against Dipylidium caninum in dogs
Pierids of the genus Euchloe Klots (Lepidoptera, Pieridae) from Siberia and the Far East.
C5A anaphylatoxin and its seven transmembrane-segment receptor
Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?
Empirical comparisons of proportional hazards regression, Poisson regression, and logistic regression in the analysis of occupational cohort data
Pollination of flowers of sweet and sour cherries
Isopodi terrestri raccolti nell' Estremo Oriente
Morphometric observations on Dipylidium caninum from dogs and cats in Austria
Chelation effectiveness of zinc proteinates demonstrated
Alopecia--a psychosomatic disease picture? I. Review of the literature
Monitoring equity in health and healthcare: a conceptual framework
Hemodynamic evaluation of the Biocor heterologous prosthesis

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial


The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial



Atherosclerosis 146(2): 369-379



ISSN/ISBN: 0021-9150

PMID: 10532693

DOI: 10.1016/s0021-9150(99)00151-3

The reported results (The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New Engl J Med 1997;336:153-162) of the Post Coronary Artery Bypass Graft (Post CABG) trial have shown that aggressive lowering was more effective than moderate lowering of low density lipoprotein (LDL) cholesterol in reducing the progression of atherosclerosis in saphenous-vein grafts (27 vs. 39%; P < 0.001); low dose warfarin had no effect on the progression of atherosclerosis. The present report describes the effect of long-term (an average of 4.3 years) aggressive treatment with high (40-80 mg/day) and moderate treatment with low (2.5-5 mg/day) doses of lovastatin on lipids, apolipoproteins (apo) and apoA- and apoB-containing lipoprotein families. To achieve the target LDL-cholesterol levels (60-85 mg/dl for aggressive group and 134-140 mg/dl for moderate group), cholestyramine (8 g/day) was given to 25% of subjects on aggressive and 5% of subjects on moderate treatment. Although with both treatment strategies there were significant decreases (P<0.001) in the levels of total cholesterol, LDL-cholesterol, apoB, LDL-apoB and cholesterol-rich Lp-B family, percent changes in the levels of these variables were greater in the aggressive- than in the moderate-treatment groups. These treatments had only marginal effects in increasing the levels of high density lipoprotein cholesterol, apoA-I and Lp-A-I and Lp-A-I:A-II families. The long-term aggressive treatment exerted no effect on the concentrations of triglycerides, apoC-IlI, apoC-III in VLDL + LDL and triglyceride-rich Lp-Bc families. Neither treatment affected the levels of Lp(a). The potentially modifying influence of warfarin and apoE phenotypes on lovastatin-induced changes in lipoprotein variables was found to be of little significance. It is likely that the beneficial effect of lovastatin in reducing the progression of atherosclerosis in grafts is mediated through its specific lowering effect on cholesterol-rich Lp-B particles.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011492171

Download citation: RISBibTeXText

Related references

Long-term effects on Clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation (New York, N.Y.) 102(2): 157-165, 2000

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 102(2): 157-165, 2000

Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation. Circulation 102(2): 144-146, 2000

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes 48(6): 1289-1294, 1999

The effect of aggressive lowering of low-density lipoprotein cholesterol levels low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The new England Journal of Medicine 336(3): 153-162, 1997

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New England journal of medicine 336(3): 153-162, 1997

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 99(25): 3241-3247, 1999

Aggressive cholesterol lowering delays saphenous vein Graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft clinical trial. Circulation (New York, N.Y.) 99(25): 3241-3247, 1999

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 104(22): 2660-2665, 2001

Optimizing cholesterol lowering therapy: contribution of the Post Coronary Artery Bypass Graft Trial. European Heart Journal 18(11): 1683-1685, 1997

Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial. American Journal of Cardiology 82(10B): 45T-48T, 1998

Benefit of aggressive lipid-lowering therapy: Insights from the post coronary artery bypass graft study and other trials. American Journal of Medicine 105(1a): 63s-68s, 1998

Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein(a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Preventive Cardiology 7(3): 106-108, 2004

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology 32(6): 1648-1656, 1998

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. Journal of Thoracic and Cardiovascular Surgery 157(1): 151-161.E1, 2019